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Charactertzatton of ‘low &,,’ 3’,5’ cychc nucleottde phosphodtesterase acttvities (PDE) expressed m mouse N 18TG3 neuroblastoma cells IS reported. 
At least 3 peaks of acttvity were isolated by DEAE chromatography. none of which was calcmm-calmodulin sttmulated and cGMP sttmulated or 
mhibtted A first peak elutes at 200 mM sodium acetate: it specifically hydrolyzes cGMP with a II’,;, of 4.7 PM and shows senstttvity to zaprinast 
[M&B 129481 (I .8 PM). A second peak elutmg at 410 mM sodturn acetate hydrolyzes both cychc nucleotides. A third peak. spectfic for CAMP 
hydrolyses. elutes at 580 mM sodtum acetate. has a K,,,, of 3.1 PM and IS senstttve to RO 20 1723 (7.6 PM) and rohpram (2 /M ). Hydrodynamtc 
analysts showed for the first peak a Stokes radius of 5.3 nm wtth a sedtmentatton coeffictent of 8 I S. a frtctional ratto tJ7f,,) of I .3l and a nattve 
molecular mass of IS? kDa. The same analysts for peak 3 showed a Stokea radius of 4 I nm wtth a sedimentatton coeffictent of 3 7 S. a fractional 
ratto of I 63 and a native molecular mass of 56 kDa The btochemtcal features reported for the enzyme eluttng m the first peak. and Its cGMP-bmding 
acttvity sttmulated by mhibttors of phosphodtesterase acttvtty. demonstrate that tt belongs to the PDE V subfamily; on the other hand the cAMP 
sprc~fic enzyme eluting m the third peak can be assigned to the ‘RO 20 1724 inhibtted’ form. The sigmficance of these findings is dtscussed m relatton 
to the functtonal characteristic5 of the NIRTG:! cell line 
Hugh affimty cychc nucleottde phosphodiesterase: PDE V subfamtly: Neuroblastoma cell: Imtdarolinone: Zaprmast 
1. INTRODUCTION 
Cyclic nucleotide phosphodiesterase (PDE) comprise 
a complex and growing group of distinct enzymes that 
differ in molecular size and charge, affinity for sub- 
strates and pharmacological inhibitors, response to 
modulators, subcellular localization and distribution 
among cells and tissues. PDEs are a main component 
of the second messenger system and thus are thought to 
be generally involved in the control of signal transduc- 
tion. Little is known. however. on the specific role of 
different PDE isoforms and on the mechanisms that 
control their expression in different cell types and their 
functional correlation. Their ability to interact with a 
large number of effecters, which can differentially mod- 
ulate the enzymatic properties of various isoenzymes. 
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.4bhrrvrurmzv PDE. phosphodtesterase; DEAE. dtethylaminoethyl. 
PBS, phosphate-buffered saline: BSA. bovme serum albumin; FPLC. 
fast performance hqutd chromatography: PMSF. phenylmethylsul- 
fonylfluortde: IBMX. tsobutylmethylxantine; zaprmaat (M&B 12948). 
1.4.dthydro-S-(2-propouyphenyll-7H-I ,2.3-triazolo[4.5-dl-pyrimidm- 
7-one: RO 20-1714. 4-[(3-butyoxy-4-methouyphenyl)methyl]-?-tmt- 
dazolidinone: roltpram (ZK 6271 I). 4-[3-cyclopentyloxy-4-metho- 
syphenyll-2 pyrrohdone: NBT. Nttrobleu tetrazolium; BCIP. 5- 
bromo-4-chloro-3-tndolyl phosphate 
suggests that they may play an important role as medi- 
ators of a variety of intracellular signals and in particu- 
lar of their integration [I]. 
This kind of function would be of particular relevance 
in the nervous system. The nervous system is character- 
ized by high PDE activity; most of the known isoforms 
are present [2]. Immunolocalization studies have shown 
selective expression of the calcium-calmodulin activated 
isoenzyme in specific neurons and its subcellular localiz- 
ation in dendrites has suggested its relation to postsyn- 
aptic signal transduction [3,4]. Little is known about 
other PDE isoforms; it is conceivable that they play 
distinct roles in specific neuronal populations and/or in 
cellular functions independent of calcium flux. 
For a better understanding of the functional role of 
the various PDE isoenzymes it would be useful to 
known in more detail their distribution in different re- 
gions of nervous system, their subcellular localization 
and their modifications in relation to different physio- 
logical and developmental states. 
Cell heterogeneity of the nervous system seriously 
hampers this type of study and makes it necessary to use 
model systems, such as neuronal cell lines. which pro- 
vide homogeneous cellular populations. Neuroblas- 
toma clones have been widely used to investigate several 
aspects of neuronal function [.5,6]. In fact. different 
clones express different specific neuronal properties, 
which can. moreover, be modulated by varying the cul- 
ture conditions; this allows to establish possible correla- 
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tions among the expression of neuronal components 
and specific functions. Thus the characterization of var- 
ious PDE isoforms in neuroblastoma clones may pro- 
vide interesting contributions for the understanding of 
their specific role in the regulation of neuronal func- 
tions. 
The presence of PDE activity in neuroblastoma cells 
has been previously reported [5,7,8]. However, no data 
are available at present on the presence of various 
isoforms. We report here the characterization of CAMP- 
cGMP phosphodiesterase activities in the N 18TG2 cell 
line. DEAE chromatography has allowed the identifica- 
tion of at least 2 distinct PDE activities. The first is a 
cGMP-specific isoenzyme, inhibited by zaprinast. 
which shows biochemical features very close to those 
described for the PDE V subfamily. The second specif- 
ically hydrolyzes CAMP and is inhibited by RO 20- 1724 
and rolipram. 
2. MATERIAL AND METHODS 
2 1 Mutrr1ul.s 
t3H]cAMP (speafic activity 28 Cilmmol) was obtamed from Amer- 
sham, [‘H]cGMP (specific activity 32.8 Ci/mmol) from New England 
Nuclear RO 30-1724 was a generous gift from Hoffman La Roche. 
rohpram (ZK 627 11) from Schering and zaprinast (M&B 22948) from 
Rh8ne-Poulenc Rorer. Leupeptm, bestatm, pepstatm, calmodulm and 
anti-rabbit antibody alkaline phosphatase conjugate were obtained 
from Sigma Chemical Co. Bovine brain calcium-calmodulm PDE was 
purified as described [9]. All other reagents. purchased from various 
sources. were of analytical grade. Culture media and sera were ob- 
tained from Flow. 
Murme neuroblastoma cells. Nl8TG2. were cultured m Dulbecco’s 
modified Eagle’s medium (DMEM) containing penicillin (5.000 IUI 
ml), streptomycin (5 mg/ml) and supplemented with 10% fetal calf 
serum (FCS). 5 x 10’ cells were plated on 90 mm culture dishes (Fal- 
con) with 10 ml medium and grown m a humidified atmosphere of 10% 
CO2 at 37°C. Confluent cultures (5 x 10b cells) were washed 2 times 
with phosphate-buffered saline (PBS) and the cells removed with 2 ml 
of PBS containmg 0.1 M EDTA. Cells were then collected by centrif- 
ugation at 800 x g for 10 mm. frozen m liquid nitrogen and stored at 
-80°C. 
Cells were suspended m homogenization buffer (20 mM HEPES pH 
7 2, 0.2 mM EGTA. 5 mM b-mercaptoethanol. 10 pg/ml leupeptm. 5 
&ml bestatm. 5pg/ml pepstatm A, 1 mM PMSF. 0 1% Trlton X-100) 
and homogenized at 4°C m a glass-teflon homogenizer with 15 
strokes. The homogenate was centrifuged for 45 min at 100.000 x g, 
the pellet was resuspended in homogenization buffer and centrifuged 
for 45 min at 100.000 x g. The first and second supernatants were then 
pooled together. The same procedure was followed m cGMP-binding 
experiments, except for homogenization buffer (10 mM phosphate 
buffer pH 7 4, 1 mM EDTA. 12 mM B-mercaptoethanol). 
2.4. DEAE chromarogrup~~j 
The supernatant was diluted 1.2 with 50 mM sodmm acetate pH 6 5, 
0.2 mM EGTA. 5 mM /?-mercaptoethanol. 0.1 mM PMSF, 5 mM 
NaF, 0.05% Triton X-100 (buffer A) and loaded onto a 5 ml DE52 
cellulose (Whatman) column equilibrated with the same buffer. After 
loading the column was washed with 5 bed volumes of buffer A and 
PDE actlvlty was eluted with 50 ml of a linear 50-l ,000 mM sodium 
acetate gradlent m buffer A, collecting 0.9 ml fractions. Fractions 
corresponding to peaks of enzyme activity were pooled and concen- 
trated with centrIcon- membranes (Amicon) for further analysis, 
2.5 Anulwc gelfrlrrurlon by FPLC 
Aliquots of the pooled fractions were loaded onto a FPLC Superose 
12 HR IO/30 (Pharmacia) column and eluted at a flow rate of 250 
pllmin with 20 mM HEPES pH 7, I mM EGTA, 5 mM ,9-mercap- 
toethanol, 5 mM MgCl:, 100 mM NaCl. 2 mM PMSF. 0.05% Triton 
x-100. 
Aliquots of pooled and concentrated fractions were layered onto a 
12 ml linear 5-20% sucrose gradient in 50 mM sodium acetate pH 6.5. 
0.2 mM EGTA. 5 mM MgCl?. 0.2 mM PMSF and centnfuged m a 
Beckman SW40 rotor for 20 h at 150.000 x g at 4°C. 0.3 ml fractions 
were collected and ahquots assayed for PDE and sedimentation stand- 
ard actlvltles. 
PDE activity was determined with the two step method as described 
[IO], in a final volume of 0.3 ml of assay buffer (60 mM HEPES pH 
7 2.0.1 mM EGTA, 5 mM MgCl:. 0.5 mg/ml BSA. 30 pglml soybean 
trypsin mhibltor) with a substrate concentration of 1 PM, unless oth- 
erwise indicated Calmodulin stimulation expenments were done using 
1 mM CaCl, and 3 ~glml of calmodulin. 
cGMP binding was measured on cell extracts, using 0.5 PM 
[‘H]cGMP m a total volume of 0.1 ml of ‘cGMP binding buffer’ (IO 
mM phosphate buffer pH 7.4. 1 mM EDTA. 12 mM /?-mercaptoetha- 
nol. 10 PM CAMP. 0.5 mg/ml BSA). The reaction was started by the 
addition of cell extract; after 120 nun m an ice-bath the assay mixtures 
were filtered onto HAWP filters (MIllpore) which were washed three 
times with 10 mM phosphate buffer pH 7.4. 1 mM EDTA After 
drying the filters were counted in 10 ml of membrane filters scmtilla- 
tion cocktail (complete LSC; Packard Instruments Co.). 
SDS-gel electrophoresls was performed on 8% slab gels [I I] and 
proteins transferred to nitrocellulose membranes as described [12]. 
The blots were then Incubated overnight at 4°C ~lth rabbit affinity 
purified polyclonal antibody against bovine brain calcium-calmodulin 
dependent PDE diluted l:l.OOO. The blot was then incubated 1 h with 
anti-rabbit antlbody conjugated to alkaline phosphatase. The im- 
munocomplexes were visualized by NBT-BCIP system Bovme brain 
calcium-calmodulm PDE was used as a positive control. 
2.10 Other prowlures 
Protem concentration was determined as described [13] using BSA 
as standard. Stokes radius [14]. native molecular mass and frlctional 
ratio [15] were calculated as previously described. 
3. RESULTS 
3.1. Erqwe extraction 
Extraction of cyclic nucleotide phosphodiesterase ac- 
tivity from NlSTG2 neuroblastoma cells is partly de- 
pendent on the presence of Triton X-100; in fact in the 
absence of Triton X-100 only 69% of the CAMP and 
80% of the cGMP hydrolytic activity was recovered, 
while using 0.1% Triton X-100, recovery was 96% and 
100%. respectively, for CAMP and cGMP activity. The 
specific activity of the enzyme extracted in the presence 
of Triton X-100 is, respectively, 0.18 nmol of CAMP 
hydrolyzed/min/mg protein and 0.15 nmol of cGMP 
hydrolyzed/min/mg protein. 
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Fig. 1, DEAE-celiuius~ ~~~~rn~tog~~~~ of N ifXGl ~~u~~~~~5t~n~~ 
extract See section 7 for detads of the procedure. Phosphodlesterase 
actlvlty was assayed m the presence of EGTA bith 1 ,uM cGMP (A.) 
and wtth I ,uM CAMP (0) as substrates. Horizontal segments above 
profile mdlcates pooled fractions 
3.2. Isc?fortt~ ~~~~r~lti~~l md i.~ur~lcf~~~~~it~~~~ 
The DEAE-chromatography elution profile (Fig. 1) 
shows the presence in these neuroblast~ma cells of at 
least 3 peaks of PDE activity, eluting, respectively. at 
200 mM (peak l), 410 mM (peak 2) and 580 mM (peak 
3) sodium acetate. Only a minor fraction (about 7%) of 
total cAMP activity was found in peak I. whiie the large 
majority was associated with peak 3; on the contrary 
70% of cGMP hydrolytic activity was eluted in peak 1 
and 30% in peak 2. Recovery of hydrolytic activity was 
80-90% in all chromatography& runs. To further charac- 
terize the kinetic and bio~hem~~l properties of the sep- 
arated isoforms, fractions corresponding to peaks 1, 2 
and 3, were pooled as indicated by the horizontal bars 
in Fig. 1. The activity present in all peaks was found 
independent of calcium-catmodulin: it was also neither 
stimulated nor inhibited by cGMP in a concentration 
range of 0.1-10 ,uM. The absence of calcium-~almod- 
Table I 
Blophysical proper&s of two phosphodlestrrase I\oform present m 
N 18TC2 ceils and comparison wtth PDE V subfamily rsoI‘orms* 
_-___. 
Rat Rat N 1 &-PC2 
lung platelets ~ 
iI31 [IhI I 3 ~.- ~---- 
Stokes radms fnm) 55 5.6 53 41 
Sednnentatlon 
coefficient (S) 78 64 81 3:! 
Native m&c&r 
mass (kDa) 177 176 I82 56 
FrictIonal 
rat10 UK) 1.54 I 48 I 41 1.63 
Kn 4.0 ND 47 3.2 -l___-- 
*All values were obtained usmg cGMP as substrates except for the 
neuroblastoma peah 3 values where CAMP was used. 
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Fg 1. L~~~wea~er.~Burk plots oi’suhstrate hydrolysis by pooled frac- 
tions from PDE acttv8ty peak& separated by DEAE-crliuiose chroma- 
ttlgl-aphy: (A) peak I. (61 peak 2. (C) peak 3 Phnsphodiesterase 
actlvlties were assayed In the presence of EGTA wtth cGMP (A) and 
CAMP (0) as substrates. 
utin isoform was also observed in the ceil extract; it was 
further confirmed by Western blot analysis. using an 
affinity purified polyclonal antibody against bovine 
brain isoform. 
Fig. 2 shows the kinetic analysis in a cancentration 
range l-.100 ,uM of cyclic nucleotides. The activities 
present in peak 1 and 3 show in Line~~eaver-..Burk plots 
a linear reiatton with substrate ~oncent~tion~ peak 1 
PDE has a Km, of 4.7 + 1.75 ,uM for cGMP and peak 3 
a K,,, 01’3.2 & 1.1 PM for CAMP; on the other hand peak 
2 displays a linear relation when cGMP is used as sub- 
strate, with a Knx of 8.X I 0.9 PM and a biphasic behav- 
iour for CAMP with two ri;,, values of 4 + 0.71 and 
30 + 2.8 ,uM. respectively. 
Sucrose density gradient analysis shows a sedimenta- 
tion constant of 8.1 S for peak 1 PDE and 3.2 S for peak 
3. FPLC gel-filtration analysis indicates a Stokes radius 
of 5.3 nm for peak 1 and 4. I nm for peak 3. As reported 
in Table I the values of mofecuiar mass and frictional 
ratio calculated from the above data are respect&&y 
182 kDa and 1.41 for peak 1 and 56 kDa and 1.63 for 
peak 3. 
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Fig. 3. (A) Inhlbition by zaprinast (M&B 22948) of PDE eluted m peak 
1 (A) and peak 2 (w). PDE activity was assayed with 1 PM cGMP as 
substrate. (B) Inhibition by RO 20-1724 (a) and rohpram [ZK 6271 l] 
(0) of PDE eluted in peak 3. PDE activity was assayed with 1 ,uM 
CAMP as substrate. 
assayed on the pooled and concentrated fractions corre- 
sponding to the isolated peaks. Zaprinast exhibits a 
high inhibitory effect on peak 1 and peak 2 activity, with 
a K, of 1.2 PM and 0.3 ,LIM, respectively (Fig. 3A). On 
the other hand only peak 3 is significantly inhibited by 
RO 20 1724. with a K, of 7.6 PM and by rolipram with 
a K, of 2 PM (Fig. 3B). 
To further characterize PDE activity of N18TG2 
cells, cGMP binding was also measured on total cell 
extracts, as described under experimental procedures. A 
cGMP binding of 1.07 pmoles of cGMP bound per mg 
of protein was measured. This activity was also found 
to be increased by a factor of 2 and 2.4, respectively, in 
the presence of 1 mM IBMX and 0.6 mM zaprinast 
(Fig. 4). 
4. DISCUSSION 
Neuroblastoma NlSTG2 cells contain ‘low K,,,’ 
CAMP and cGMP PDE activities. Requirement of Tri- 
ton X-100 for solubilization is different for the two 
activities, indicating a higher degree of hydrophobicity 
for CAMP-specific PDE, which not only is extracted at 
a lower extent in the absence of Triton X-100 as com- 
pared to cGMP PDE, but also needs 0.05% Triton X- 
100 in all performed chromatographic separations. 
On the basis of DEAE elution profile, hydrodynamic 
and kinetic properties and inhibition studies we have 
demonstrated the presence of at least 3 distinct peaks, 
each one using as substrate either CAMP or cGMP; all 
three enzymes are neither stimulated by cGMP or cal- 
cium-calmodulin nor inhibited by cGMP. 
cGMP hydrolytic activity eluting at the lowest ionic 
strength (Fig. 1) on the basis of its Km, sedimentation 
constant, native molecular mass and Stokes radius val- 
ues can be designated as a member of the ‘cGMP bind- 
ing-cGMP specific PDE’ family, characterized in rat 
lung [16,17], bovine lung [18] and rat platelets [19,20] 
(Table I). Further data in favour of this assignment are 
zaprinast inhibition [21] and cGMP binding activity, 
shown respectively in Figs. 3 and 4. Moreover this 
isoenzyme displays the property that IBMX or zapri- 
nast inhibition of PDE catalytic site stimulates cGMP 
binding activity [22,23]. These features together with the 
absence of effect on enzyme activity by cGMP and 
calmodulin indicate that peak 1 cGMP PDE belongs to 
PDE V family. This PDE isoform is not the only one 
present in peak 1. In fact the coeluting CAMP hydrolytic 
activity can be separated by gel filtration and sucrose 
gradient from cGMP peak 1 activity. 
cGMP PDE isoforms eluted in peak 1 and 2 differ for 
their K,,, values and zaprinast inhibition; however their 
hydrodynamic features (data not shown), as well as 
their substrate specificity are very similar. The two en- 
zyme molecules thus appear as closely related proteins. 
Their different behaviour in DEAE chromatography 
may be dependent on posttranslational modifications of 
a single protein or to a rather stable binding with some 
small molecules, as shown for the cGMP-PDE from 
bovine lung [ 181. PDE activity eluting in peak 3 specifi- 
cally hydrolyzes CAMP; this characteristic together with 
its hydrodynamic and inhibition properties allows to 
classify it as ‘low K,,,’ RO 20 1724 inhibited form’ 
[24,25]. This PDE family is widely distributed in several 
tissues and has been studied in details in mammalian 
liver [26]. kidney [27], testis [28] and brain [29]. In all 
these tissues a certain degree of hydrophobicity and 
molecular asymmetry, resulting in a particularly high 
frictional ratio. is evident; similar characteristics are 
found in N 18TG2 cells (Table I). The shape of peak 3 
suggests that this activity is not due to a single enzyme 
but that several related isoforms, eluting in a very close 
rl 
SUP ibmx zap 
Fig. 4. Effects of PDE mhibltors on cGMP binding; sup, neuroblas- 
toma supernatant binding . mix. bmdmg in the presence of 1 mM 
IBMX. zap, binding in the presence of 0.6 mM of zaprinast. 
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range of ionic strength, are present. Indirect evidence 
for the heterogeneity of this PDE family is provided by 
gene cloning analysis from mammalian tissues, which 
has isolated four cDNAs corresponding to distinct but 
homologous genes: transcripts of three of these genes 
are found in high amount in brain [30.31]. 
In conclusion from the studies reported here on the 
characterization of PDEs in N 18TG3 neuroblastoma 
clone two findings appear particularly relevant: the ab- 
sence of calcium-calmodulin dependent PDE isoforms. 
which are predominant in brain, and the presence of 
cGMP PDE V. These differences of NlSTG2 PDE pat- 
tern, as compared with brain, are not surprising. In fact 
it is known that calmodulin-dependent PDE is not ubiq- 
uitously distributed in all central neurons [4]; further- 
more it has not been found in sympathetic neurons of 
the superior cervical ganglia [32]. It should be noted that 
N18TG2 is the first cell line so far demonstrated to 
express high level of PDE V: it therefore can be an 
interesting mode1 to investigate PDE V role in cGMP 
metabolism and of neuronal subpopulations not ex- 
pressing calmodulin dependent PDE isoforms; it thus 
could be particularly suitable for a better characteriza- 
tion of PDE V properties and functions in relation to 
neuron specificity and possibly differentiation. 
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